- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04748900
Physiotherapy Treatment Plan in Allergic Bronchopulmonary Aspergillosis: Case Report
February 9, 2021 updated by: JORGE VELAZQUEZ SAORNIL, Universidad Católica de Ávila
Effects of a Respiratory Physiotherapy Treatment Plan in Allergic Bronchopulmonary Aspergillosis: Case Report
A spirometry study is performed in a patient diagnosed with allergic bronchopulmonary aspergillosis.
An initial measurement is carried out and the patient is then put on a four-week physiotherapy treatment plan.
Four spirometry measurements were taken to assess different variables and an improvement in all the spirometry values was established.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ávila, Spain, 05005
- Universidad Católica de Ávila
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
Patient with respiratory insufficiency due to allergic bronchopulmonary aspergillosis
Description
Inclusion Criteria:
- woman
- diagnosis of respiratory insufficiency due to allergic bronchopulmonary aspergillosis
- over 50 years of age
- under 80 years of age
Exclusion Criteria:
- male
- not have a diagnosis of respiratory insufficiency due to allergic bronchopulmonary aspergillosis
- under 50 years of age
- over 80 years of age
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total volume
Time Frame: 3 months
|
ml
|
3 months
|
|
Vital capacity
Time Frame: 3 months
|
ml
|
3 months
|
|
Expiratory reserve volume
Time Frame: 3 months
|
ml
|
3 months
|
|
Inspiratory reserve volume
Time Frame: 3 months
|
ml
|
3 months
|
|
Inspiratory capacity
Time Frame: 3 months
|
ml
|
3 months
|
|
Inspiration time
Time Frame: 3 months
|
seconds
|
3 months
|
|
Expiratory time
Time Frame: 3 months
|
seconds
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total time
Time Frame: 3 months
|
seconds
|
3 months
|
|
Percentage inspiratory time
Time Frame: 3 months
|
seconds
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jorge V Saornil, PhD, Universidad Católica de Ávila
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Bonaiti G, Merati V, Pesci A, Faverio P. Allergic bronchopulmonary aspergillosis screening in bronchiectasis: is there always a precise answer to a clear question? Eur Ann Allergy Clin Immunol. 2019 Jan;51(1):41-43. doi: 10.23822/EurAnnACI.1764-1489.62. No abstract available.
- Cui L, Liu H, Sun L. Multidisciplinary respiratory rehabilitation in combination with non-invasive positive pressure ventilation in the treatment of elderly patients with severe chronic obstructive pulmonary disease. Pak J Med Sci. 2019 Mar-Apr;35(2):500-505. doi: 10.12669/pjms.35.2.459.
- Lareau SC, Fahy B. Pulmonary Rehabilitation. Am J Respir Crit Care Med. 2018 Nov 15;198(10):P19-P20. doi: 10.1164/rccm.19810P19. No abstract available.
- Patel G, Greenberger PA. Allergic bronchopulmonary aspergillosis. Allergy Asthma Proc. 2019 Nov 1;40(6):421-424. doi: 10.2500/aap.2019.40.4262.
- Oguma T, Taniguchi M, Shimoda T, Kamei K, Matsuse H, Hebisawa A, Takayanagi N, Konno S, Fukunaga K, Harada K, Tanaka J, Tomomatsu K, Asano K. Allergic bronchopulmonary aspergillosis in Japan: A nationwide survey. Allergol Int. 2018 Jan;67(1):79-84. doi: 10.1016/j.alit.2017.04.011. Epub 2017 May 23.
- HINSON KF, MOON AJ, PLUMMER NS. Broncho-pulmonary aspergillosis; a review and a report of eight new cases. Thorax. 1952 Dec;7(4):317-33. doi: 10.1136/thx.7.4.317. No abstract available.
- Denning DW, Pleuvry A, Cole DC. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol. 2013 May;51(4):361-70. doi: 10.3109/13693786.2012.738312. Epub 2012 Dec 4.
- Kalaiyarasan, Jain AK, Puri M, Tayal D, Singhal R, Sarin R. Prevalence of allergic bronchopulmonary aspergillosis in asthmatic patients: A prospective institutional study. Indian J Tuberc. 2018 Oct;65(4):285-289. doi: 10.1016/j.ijtb.2018.04.007. Epub 2018 Apr 13.
- Sehgal IS, Choudhary H, Dhooria S, Aggarwal AN, Bansal S, Garg M, Behera D, Chakrabarti A, Agarwal R. Prevalence of sensitization to Aspergillus flavus in patients with allergic bronchopulmonary aspergillosis. Med Mycol. 2019 Apr 1;57(3):270-276. doi: 10.1093/mmy/myy012.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2020
Primary Completion (Actual)
February 3, 2021
Study Completion (Actual)
February 5, 2021
Study Registration Dates
First Submitted
February 5, 2021
First Submitted That Met QC Criteria
February 9, 2021
First Posted (Actual)
February 10, 2021
Study Record Updates
Last Update Posted (Actual)
February 10, 2021
Last Update Submitted That Met QC Criteria
February 9, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Bacterial Infections and Mycoses
- Respiratory Hypersensitivity
- Hypersensitivity
- Mycoses
- Lung Diseases, Fungal
- Lung Diseases
- Lung Diseases, Obstructive
- Aspergillosis
- Pulmonary Aspergillosis
- Aspergillosis, Allergic Bronchopulmonary
Other Study ID Numbers
- 04/02/2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
-
Mylan Inc.Theravance BiopharmaCompletedChronic Obstructive Pulmonary Disease, COPDNew Zealand
-
AstraZenecaParexel International Ltd; Cognizant Technology Solution; Center for Information... and other collaboratorsCompletedChronic Obstructive Pulmonary Disease COPDUnited States, Canada, France, Russian Federation, Ukraine, Hungary, Bulgaria
-
University of ZurichNational Center of Cardiology and Internal Medicine named after academician...CompletedChronic Obstructive Pulmonary Disease (COPD)Kyrgyzstan
-
Novartis PharmaceuticalsCompletedChronic Obstructive Pulmonary Disease, COPDGermany
-
AstraZenecaQuintiles, Inc.Completed
-
University of LeipzigTNI Medical AGCompletedCOPD Chronic Obstructive Pulmonary DiseaseGermany
Clinical Trials on spirometer
-
Mayo ClinicCompletedPulmonary EmbolismUnited States
-
Lahey ClinicCompletedPneumonia | Pulmonary Atelectasis | Obesity, Morbid | Complications of Bariatric ProceduresUnited States
-
Fu Jen Catholic UniversityNot yet recruitingChronic Obstructive Pulmonary Disease (COPD) | SpirometryTaiwan
-
Carmel Medical CenterCompletedSigns and Symptoms, Respiratory | Allergy | Bronchial AsthmaIsrael
-
Carmel Medical CenterCompletedSigns and Symptoms, Respiratory | Allergy | Bronchial AsthmaIsrael
-
Carmel Medical CenterCompletedSigns and Symptoms, Respiratory | Allergy | Bronchial AsthmaIsrael
-
Air Liquide SAInamedCompletedHealthy | Chronic Obstructive Pulmonary Disease | AsthmaGermany
-
Cairo UniversityRecruitingEnd Stage Renal Disease | HemolysisEgypt
-
National Taipei University of Nursing and Health...Tri-Service General HospitalNot yet recruitingHypertension | Diabetes | Long COVID | Cardiac Disease | COVID-19 Pandemic
-
University of NottinghamAstraZenecaRecruitingChronic Obstructive Pulmonary Disease | AsthmaUnited Kingdom